Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

Open Access 01-11-2016 | Editorial Commentary

ImmunoPET to help stratify patients for targeted therapies and to improve drug development

Authors: Françoise Kraeber-Bodere, Clément Bailly, Michel Chérel, Jean-François Chatal

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 12/2016

Excerpt

Malignant tumours usually display intratumoral heterogeneity as well as phenotypic and genotypic heterogeneity among patients. Consequently, there is the need to develop treatments appropriate to each patient [1]. Screening of tumour phenotypes requires biopsy, a procedure that is invasive and limited to accessible tumour sites. Moreover, it is difficult to obtain repeated biopsies from the same lesions to explore changes in properties and heterogeneity during therapy. There is therefore the need for new noninvasive diagnostic technologies such as molecular imaging to assess whole-body tumour phenotypes to allow more specific therapeutic strategies to be developed. …

Tabassum DP, Polyak K. Tumorigenesis: it takes a village. Nat Rev Cancer. 2015;15:473–83.CrossRefPubMed

Lamberts LE, Williams SP, Terwisscha van Scheltinga AGT, Lub-de Hooge MN, Schröder CP, Gietema JA, et al. Antibody positron emission tomography imaging in anticancer drug development. J Clin Oncol. 2015;33:1491–504.CrossRefPubMed

Boerman OC, Oyen WJ. Immuno-PET of cancer: a revival of antibody imaging. J Nucl Med. 2011;52:1171–2.CrossRefPubMed

Kraeber-Bodéré F, Rousseau C, Bodet-Milin C, Mathieu C, Guérard F, Frampas E, et al. Tumor immunotargeting using innovative radionuclides. Int J Mol Sci. 2015;16:3932–54.CrossRefPubMedPubMedCentral

Sun H, England CG, Hernandez R, Graves SA, Majewski RL, Kamkaew A, et al. ImmunoPET for assessing the differential uptake of a CD146-specific monoclonal antibody in lung cancer. Eur J Nucl Med Mol Imaging. 2016. doi:10.1007/s00259-016-3442-1

Divgi CR, Pandit-Taskar N, Jungbluth AA, Reuter VE, Gönen M, Ruan S, et al. Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. Lancet Oncol. 2007;8:304–10.CrossRefPubMed

Divgi CR, Uzzo RG, Gatsonis C, Bartz R, Treutner S, Yu JQ, et al. Positron emission tomography/computed tomography identification of clear cell renal cell carcinoma: results from the REDECT trial. J Clin Oncol. 2013;31:187–94.CrossRefPubMed

Dijkers EC, Kosterink JG, Rademaker AP, Perk LR, van Dongen GA, Bart J, et al. Development and characterization of clinical-grade 89Zr-trastuzumab for HER2/neu immunoPET imaging. J Nucl Med. 2009;50:974–81.CrossRefPubMed

Baum RP, Prasad V, Müller D, Schuchardt C, Orlova A, Wennborg A, et al. Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In- or 68Ga-labeled affibody molecules. J Nucl Med. 2010;51:892–7.CrossRefPubMed

10.

Tamura K, Kurihara H, Yonemori K, Tsuda H, Suzuki J, Kono Y, et al. 64Cu-DOTA-trastuzumab PET imaging in patients with HER2-positive breast cancer. J Nucl Med. 2013;54:1869–75.CrossRefPubMed

11.

Jauw YW, Menke-van der Houven van Oordt CW, Hoekstra OS, Hendrikse NH, Vugts DJ, Zijlstra JM, et al. Immuno-positron emission tomography with zirconium-89-labeled monoclonal antibodies in oncology: what Can We learn from initial clinical trials? Front Pharmacol. 2016;7:131.CrossRefPubMedPubMedCentral

12.

Gebhart G, Lamberts LE, Wimana Z, Garcia C, Emonts P, Ameye L, et al. Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial. Ann Oncol. 2016;27:619–24.CrossRefPubMed

13.

Bahce I, Huisman MC, Verwer EE, Ooijevaar R, Boutkourt F, Vugts DJ, et al. Pilot study of (89)Zr-bevacizumab positron emission tomography in patients with advanced non-small cell lung cancer. EJNMMI Res. 2014;4:35.CrossRefPubMedPubMedCentral

14.

Menke-van der Houven van Oordt CW, Gootjes EC, Huisman MC, Vugts DJ, Roth C, Luik AM, et al. 89Zr-cetuximab PET imaging in patients with advanced colorectal cancer. Oncotarget. 2015;6:30384–93.PubMedPubMedCentral

15.

van Asselt SJ, Oosting SF, Brouwers AH, Bongaerts AHH, de Jong JR, Lub-de Hooge MN, et al. Everolimus reduces (89)Zr-bevacizumab tumor uptake in patients with neuroendocrine tumors. J Nucl Med. 2014;55:1087–92.CrossRefPubMed

16.

den Hollander MW, Bensch F, Glaudemans AW, Oude Munnink TH, Enting RH, den Dunnen WF, et al. TGF-β antibody uptake in recurrent high-grade glioma imaged with 89Zr-fresolimumab PET. J Nucl Med. 2015;56:1310–4.CrossRef

17.

Muylle K, Flamen P, Vugts DJ, Guiot T, Ghanem G, Meuleman N, et al. Tumour targeting and radiation dose of radioimmunotherapy with (90)Y-rituximab in CD20+ B-cell lymphoma as predicted by (89)Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximab. Eur J Nucl Med Mol Imaging. 2015;42:1304–14.CrossRefPubMedPubMedCentral

Title: ImmunoPET to help stratify patients for targeted therapies and to improve drug development
Authors: Françoise Kraeber-Bodere
Clément Bailly
Michel Chérel
Jean-François Chatal
Publication date: 01-11-2016
Publisher: Springer Berlin Heidelberg
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 12/2016
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-016-3458-6

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

ImmunoPET to help stratify patients for targeted therapies and to improve drug development

Excerpt

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 12/2016

Comparison between MRI-based attenuation correction methods for brain PET in dementia patients

Synthesis and preclinical evaluation of an Al18F radiofluorinated GLU-UREA-LYS(AHX)-HBED-CC PSMA ligand

18F-FDG PET/CT imaging factors that predict ischaemic stroke in cancer patients

Paraneoplastic syndrome demonstrated on 99mTc-HMDP bone scan

Comments on Van den Wyngaert et al., The EANM practice guidelines for bone scintigraphy

Feasibility and acceptance of simultaneous amyloid PET/MRI